quasia

Quassia (Quassia amara L.): A Comprehensive Reference

1. Identity: Botanical Classification, Natural Source, and Common Names

Quassia is the common name applied principally to Quassia amara L., an attractive small evergreen shrub or tree from the tropics belonging to the family Simaroubaceae. Worldwide known as "bitterwood," the plant grows in sandy soils of lowland and highland forests, wet forests along riverbanks, and is native to Central Mexico to southern tropical America and Guadalupe. The species epithet amara means "bitter" in Latin and describes its very intense taste.

Quassia amara is marketed and used interchangeably with another tree species, Picrasma excelsa, sharing the common name of quassia and many of Quassia amara's constituents and uses. P. excelsa is with up to 25 m in height much taller, and occurs farther north in the tropics of Jamaica, the Caribbean, the Lesser Antilles, and northern Venezuela than Quassia amara. In herbal medicine in the United States and Europe, very little distinction is made between these two species; they are used identically and simply called quassia.

Common and vernacular names are numerous. The ethnobotany database lists the following common names: Amargo, Bitterwood, Quassia, Cuassia, Guabo, Hombre grande, Jamaica bark, Palo muneco, Pau amarelo, Pau quassia, Quassia de caiena, Quassia amarga, Quassia wood, Ruda, Simaruba, Surinam quassia, Surinam wood, and Wewe gifi. Additional names include Bitter Ash, Bitterholz, Bois amer, Bois de quassia, Crucete, Fliegenholz, Kashshing, Marauba, Marupa, Quassiaholz, Quassie, Quina, Simarubabaum, and Suriname wood.

Botanical description. It is a small, multi-stemmed and slow-growing tree with disorderly, twiggy limbs, reaching a height up to 6 metres. The pinnate leaves with 3–5 leaflets are deeply veined, polished, alternately arranged, and dark green, 15–25 cm long, distinctive for their broadly winged axis and reddish veins. The plant produces small, red to purple flowers, which are followed by fruit that are berry-like in appearance.

Commercial forms and preparations. Quassia amara is sold in the form of ground-up chips that are used to produce tonics or tinctures, which are made by soaking the bark in water for a long time. All plant parts are useful for medicinal properties, and the bark extracts are mainly used as flavoring in drinks but also for insecticides; trunk wood, roots, bark, stems, leaves, flowers, and seeds are harvested to gain extracts. Amargo wood and extracts of the wood are listed by the U.S. Food and Drug Administration (FDA) as generally regarded as safe (GRAS). The wood and its main bitter chemical, quassin, are also approved as food additives and are employed in beverages and baked goods for their bitter taste.

2. History and Traditional Use

2.1 Naming and Discovery

The genus was named by Carl Linnaeus, who named it after the first botanist to describe it: the Surinamese freedman Graman Quassi. Q. amara was named after Graman Quassi, a healer and botanist who showed Europeans the plant's fever-treating uses. A Surinamese man named Quassia gained attention for treating fevers with a secret remedy based on this herb in the 18th century; Rolande took it to Sweden in 1756 and disseminated its medicinal reputation across Europe.

2.2 Indigenous Traditions in the Americas

Quassia amara traces back to pre-Columbian herbal lore: indigenous peoples of the Amazon basin used its wood chips as a digestive bitter and as a febrifuge. In South American indigenous traditions, particularly among communities in Suriname, Guyana, and Brazil, the wood was prepared as a cold infusion called "bitterwood tea" for fevers, intestinal worms, digestive complaints, and as an insecticide applied topically for lice.

Despite this, the tropics have a long history of using Q. amara for therapeutic purposes. Root infusion is used to reduce malarial fever. Bark and its decoction are used as a blood purifier, anti-diarrheal, anti-dysenteric, and anti-malarial; macerated inner bark decoction is drunk to treat colds by the Guyana Patamona. Across Jamaica and the wider Caribbean, herbalists used the bark to "clean the blood" and expel intestinal worms, while in Brazil and Venezuela, traditional healers brewed it as a digestive tonic for people recovering from illness.

One of the most popular remedies in French Guiana is made from Quassia amara leaves, sometimes referred to as "Cayenne's quinquina" due to its bitter taste and its febrifuge properties. In Brazil, Quassia amara is known as "false quinine."

2.3 European Adoption

European pharmacopoeias formally recognized Quassia wood (Lignum Quassiae) as an official bitter tonic well into the 20th century, and it was historically used as a non-alcoholic flavoring substitute for hops. In herbal medicine in the United States and Europe, amargo is employed as a bitter tonic for stomach, gallbladder, and other digestive problems (by increasing the flow of bile, digestive juices, and saliva); as a laxative, amebicide, and insecticide; and to expel intestinal worms. Infusions of quassia chips were reintroduced on a wide scale in Denmark when DDT-resistant lice emerged.

2.4 Traditional Preparations in Other Cultures

In Indonesian Jamu—the traditional herbal medicine system of the archipelago—Quassia preparations are integrated into bitter tonic formulas targeting fever management and malaria-associated symptoms, aligning with its demonstrated bioactivity against Plasmodium species. Quassin is a white crystalline substance widely used in Chinese herbal medicine for its bitter taste.

Certain tribes have used the plant to treat measles and fever, and as a mouthwash. The extracts and purified mixtures of bitter principles ("quassin") have been used to give a bitter taste to various food products, especially alcoholic (e.g., bitters, liqueurs) and non-alcoholic beverages, desserts, candy, baked goods, and puddings.

3. Key Constituents and Active Compounds

3.1 Quassinoids (Primary Bitter Principles)

Quassinoids are the important phytoconstituents of this plant and are the main bitter principles of Quassia amara. The plant contains diverse bioactive compounds, primarily quassinoids, with over 170 types identified. These bioactive phytochemical agents belong to the triterpene chemical family, and are found mostly in Simaroubaceae species.

Quassia's defining chemistry comes from quassinoids, a group of highly oxygenated degraded triterpenes that are responsible for much of the plant's intense bitterness and much of its research interest. Among the best-known compounds are quassin, neoquassin, simalikalactone D, and simalikalactone E—names that appear most often when scientists investigate Quassia's antimalarial, anti-inflammatory, antiparasitic, cytotoxic, and digestive-related effects.

Quassinoids, comprising approximately 0.25% of quassia wood, exhibit various health benefits, including anti-malarial and anti-inflammatory effects, indicated by IC₅₀ values of 10 nM against Plasmodium falciparum.

3.2 Alkaloids

Both quassia species contain alkaloids (approximately 0.25%), such as canthin-6-one, 5-methoxycanthin-6-one, and carboline alkaloids. Quassin and the alkaloid 2-methoxycanthin-6-one have been isolated from the plant. The alkaloid 2-methoxycanthin-6-one has been specifically implicated in antiulcer mechanisms (see Section 5.2).

3.3 Other Terpenoids and Compounds

Terpenoids in one or both species include isoquassin and mixtures of bitter principles (said to be 50 times more bitter than quinine), including quassin, neo-quassin, and 18-hydroxyquassin. Its bark and wood contain triterpenes, indole alkaloids, quassinoids, canthinones, and scopoletin.

3.4 Mechanisms of Action

Digestive/bitter effects. Quassia contains chemicals that might increase stomach acid and bile secretions, perhaps accounting for appetite stimulant and digestive effects. The amaroid drug (quassinoids) stimulates secretion of gastric juices, increases appetite, and aids digestion; it may also have a choleretic effect.

Antimalarial action. The main bioactive constituents of Quassia amara are quassinoids, which had been found to be active against chloroquine-resistant Plasmodium falciparum. A known quassinoid, simalikalactone D (SkD), was identified as the active compound, with an IC₅₀ value of 10 nM against FcB1 Plasmodium falciparum chloroquine-resistant strain in vitro. Simalikalactone D is noxious for mid-trophozoite Plasmodium falciparum stage, and its antimalarial activity is concomitant with the S phase of the parasite's cell cycle. SkD synergizes in vitro with atovaquone against P. falciparum, and the SkD/atovaquone combination acts on P. falciparum mitochondria.

Antiulcer mechanisms. 2-Methoxycanthin-6-one is one of the antiulcer principles in Quassia amara extract whose detailed pharmacological actions are under investigation for potential development of potent antiulcer agents.

Insecticidal action. The major insecticidal principle is quassin, a degraded triterpenoid (decanortriterpenoid). Quassins act by direct contact or by ingestion on the insect's nervous system with an action similar to that of pyrethrum, although less incisive and rather slow; parasites that come into contact with quassia experience a gradual decrease in vital activities, with subsequent paralysis and death.

Male antifertility effects. Quassia amara extract and quassin have been reported to possess potent male antifertility activities in both in vivo and in vitro animal models. The crude methanol extract of the stem wood of Quassia amara L. inhibited both the basal and LH-stimulated testosterone secretion of rat Leydig cells in a dose-dependent fashion; fractionation of the extract gave quassin and 2-methoxycanthin-6-one, with quassin proving to be the bioactive agent.

4. Scientific Evidence by Area of Use

4.1 Pediculosis (Head Lice)

Topical application for head lice represents the area with the most direct human clinical evidence for quassia.

454 patients were treated with quassia tincture for head lice; at examination one week later only three patients had hatched lice, and there was firm evidence that these patients had been reinfested. The treatment procedure was acceptable to both patients and staff, and no side effects were observed. As resistance to clophenothane (DDT) emerged, this study confirmed earlier reports on the effectiveness of quassia tincture as a useful alternative. The recommended treatment in that study was two applications with an interval of one week.

In another study conducted in a double-blind design versus placebo, involving 148 children with pediculosis, those treated with quassia extract reported a lesser number of new cases, demonstrating a preventive effect against lice.

In a more recent clinical study, a product free of chemical insecticides, containing Andiroba oil (which asphyxiates the lice) and quassia vinegar (which dissolves the chitin of the nits) was applied to 30 patients with head lice infestation, aged 3–39 years, one to three times 5 days apart. Cure was defined as absence of live lice after 5, 10, or 14 days. Easiness and safety were also assessed. Overall cure rates were 20% on Day 5 after one treatment, 37% on Day 10 after two treatments, and 90% on Day 14 after three treatments.

A subsequent study investigated physical factors related to the efficacy of a new louse treatment with 5% Quassia amara using a factorial model. Products containing quassia are rarely associated with resistance phenomena and have a far lower risk of toxicity than comparable insecticides.

Evidence strength: The head lice indication has the largest body of direct human evidence for quassia. An early uncontrolled study of 454 patients showed near-complete efficacy; a double-blind study in 148 children demonstrated a preventive effect. These results are clinically meaningful, though the studies are older, used variable preparations, and most lack robust randomized controlled trial (RCT) designs.

4.2 Rosacea and Seborrheic Dermatitis (Topical Use)

An open-label study investigated the efficacy and safety of a topical gel with 4% Quassia amara extract in the treatment of various grades of rosacea (I–IV), involving 30 patients treated for 6 weeks; response was evaluated by flushing, erythema, telangiectasia, papules, and pustules scores. Twenty-seven of 30 patients (90%) completed the study. The treatment resulted to be very effective, with results in line with those published for topical metronidazole and azelaic acid. No side effects such as pruritus, edema, or stinging were observed. The clinical overall improvement was similar to conventional standard treatments, though no control group was included in this study (Level of Evidence B).

In a subsequent randomized, double-blind, parallel-group study comparing 4% quassia amara extract (QAE) cream with 0.75% metronidazole cream, it was demonstrated that topical QAE had a more rapid and higher efficacy than metronidazole on rosacea symptoms. While both drugs acted similarly on papules and pustules, the efficacy of QAE was higher than metronidazole on erythema, flushing, and telangiectasiae, where metronidazole has no activity. Additional clinical trials involving larger groups of patients were noted as warranted to confirm these results.

For seborrheic dermatitis, a randomized, double-blind, comparative study checked the efficacy and safety of a topical gel with 4% Quassia amara extract and compared it with topical 2% ketoconazole and 1% topical ciclopiroxolamine in the treatment of facial seborrheic dermatitis, in 60 patients randomly distributed in 3 groups. Of the 60 patients, 54 (90%) completed the study; the three therapeutic options all resulted to be very effective, with a significant advantage in efficacy for 4% Quassia extract. The conclusion was that topical gel with 4% Quassia extract represents a new, safe, and effective treatment for facial seborrheic dermatitis.

In a recent review on herbal products for rosacea, a 4% extract from Simarouba amara (quassia) was the only herbal product that reduced telangiectasia.

Evidence strength: Topical use in rosacea and seborrheic dermatitis has the best direct human clinical support among quassia's applications. A double-blind, randomized comparative trial for seborrheic dermatitis and a double-blind RCT versus metronidazole for rosacea exist, though trials involve relatively small patient populations, and studies on seborrheic dermatitis did not include a placebo arm. Overall evidence is promising but preliminary.

4.3 Antimalarial Activity

Simalikalactone D is responsible for the antimalarial properties of an Amazonian traditional remedy made with Quassia amara L. leaves. The traditional antimalarial remedy most widespread in French Guiana is a simple tea made from Quassia amara leaves, and this herbal tea displays excellent antimalarial activity both in vitro and in vivo. The compound simalikalactone D inhibits 50% of Plasmodium yoelii yoelii rodent malaria parasite at 3.7 mg/kg/day in vivo by the oral route.

A related quassinoid, simalikalactone E (SkE), was also investigated: this new molecule inhibited the growth of Plasmodium falciparum cultured in vitro by 50%, at concentrations ranging from 24 to 68 nM, independently of the strain sensitivity to chloroquine, and also decreased gametocytemia with a 50% inhibitory concentration sevenfold lower than that of primaquine. SkE was found to be less toxic than simalikalactone D, and in vivo, inhibited murine malaria growth of Plasmodium vinckei petteri by 50% at 1 and 0.5 mg/kg of body weight per day by oral or intraperitoneal routes, respectively.

Both biological antimalarial activity and cytotoxicity of the leaf tea remedy have been attributed solely to the presence of simalikalactone D. It was concluded that this preparation should not be recommended for treatment of malaria until a clinical study in humans is performed. The same research also emphasizes that human clinical data are insufficient and that traditional leaf tea should not simply be recommended as malaria treatment without proper clinical study.

Evidence strength: Evidence is entirely preclinical (in vitro and animal studies). The in vitro and rodent model data are scientifically notable—particularly the low IC₅₀ values of simalikalactone D—but no human clinical trials for malaria treatment have been published.

4.4 Gastrointestinal Effects (Antiulcer, Digestive)

Pharmacologically, Quassia bark/wood extracts provide an excellent preventive effect in gastric ulcer models at low dose with no toxicity. In one PMC-indexed rat study, 2-methoxycanthin-6-one was demonstrated as one of the antiulcer principles in Quassia amara extract, with efforts in progress to investigate other possible mechanisms of antiulcer effect.

The digestive bitter effect—stimulation of gastric secretions and appetite—is traditionally well established, but traditional digestive bitter use is plausible, though not strongly validated by modern clinical trials. No published human RCTs examining quassia specifically for digestive complaints, functional dyspepsia, or peptic ulcers could be identified in the peer-reviewed literature.

Evidence strength: Antiulcer and digestive effects are supported only by animal and in vitro data. The mechanistic rationale (bitter receptor stimulation, gastric acid modulation) is scientifically plausible, but direct human clinical evidence is lacking.

4.5 Antidiabetic / Antihyperglycemic Effects

Quassia amara extract effectively normalized diabetes and associated hyperlipidemia in nicotinamide-streptozotocin induced diabetic rats. Ethnomedicinally, this plant has anti-diabetic properties due to the bitterest substance quassia present in it, and is used in the management of type 2 diabetes.

Evidence strength: Antidiabetic activity has been documented in animal models only. No human clinical trials have been published. Evidence is preliminary.

4.6 Anti-inflammatory and Antinociceptive Effects

Different extracts from the bark of Quassia amara were evaluated for possible antiedematogenic, antinociceptive, and sedative effects. Oral administration (100, 250, and 500 mg/kg) did not show significant effects; however, when administered intraperitoneally, the hexane extract decreased paw edema induced by carrageenan, showed antinociceptive effects on the hot-plate test and on acetic acid-induced writhing, and showed sedative effects on pentobarbital-induced sleep.

Since the discovery of quassinoids, studies have indicated that they display a wide range of biological and pharmacological effects, including antitumor, antimalarial, anti-inflammatory, antifeedant, insecticidal, amoebicidal, antiulcer, and herbicidal activities.

Evidence strength: Anti-inflammatory and antinociceptive effects are animal model findings only. Intraperitoneal—rather than oral—administration was required for significant effects in rodents, limiting direct translational relevance.

4.7 Antitumor and Antileukemic Activity

The renewed interest in bitterwood as a source of pharmacological compounds has allowed characterization of new and promising effects of quassimarin and simalikalactone D isolated from its leaves, mainly as antimalarial, anti-HIV virus, and antitumoral compounds. However, the clinical record on antitumor applications is limited and mixed: due to serious toxicity (hypotension, nausea, vomiting, and fever) and poor efficacy, clinical trials of bruceantin—a related quassinoid—failed.

Evidence strength: Antitumor and antileukemic activities have been noted in vitro. The failed clinical trials of the closely related compound bruceantin serve as a cautionary precedent for translating quassinoid antitumor findings to clinical outcomes.

4.8 Antiparasitic (Intestinal Worms / Amoebiasis)

Traditionally, Quassia amara has antimalarial, stomachic, antianaemic, antibiotic, cytotoxic, and antiamoebic activity. Its reproductive, insecticidal, larvicidal, and vermifuge properties have also been reported in the literature. Fresh bark, leaves, or wood extracts are used to treat digestive problems, malaria, and hepatic disorders.

Evidence strength: Antiparasitic properties beyond head lice are supported primarily by traditional use and in vitro or animal data. No human RCTs for intestinal parasites have been identified.

5. Body Systems and Health Areas Associated with Quassia

• Gastrointestinal system: Bitter tonic, appetite stimulation, secretion of gastric juice and bile, antiulcer, anti-dysenteric, antidiarrheal, antiamoebic, anthelmintic (worm expulsion).
• Dermatological system: Head lice treatment (topical insecticide), rosacea, seborrheic dermatitis (topical anti-inflammatory, antiparasitic against Demodex).
• Immune and infectious disease: Antimalarial (anti-Plasmodium), antibacterial, antifungal, antiviral (preclinical anti-HIV data only), antileishmanial.
• Metabolic and endocrine: Antidiabetic, antihyperglycemic (animal data only).
• Male reproductive system: Antifertility effect (animal data; quassin-mediated suppression of testosterone and sperm function — see Section 7 for safety implications).
• Central nervous system: Sedative and muscle relaxant effects observed in rodents following intraperitoneal administration.
• Oncology: Antitumor and antileukemic activity in vitro; clinical translation has not yet been demonstrated.

6. Dosage Forms and Reported Dosages

Quassia wood has been used as a bitter tonic, with a typical oral dose of 500 mg. No studies have been performed to support this dose.

Extracts and purified mixtures of bitter principles ("quassin") have been used to give a bitter taste to various food products, especially alcoholic (e.g., bitters, liqueurs) and non-alcoholic beverages, desserts, candy, baked goods, and puddings.

For the head lice studies: the recommended treatment in the principal 454-patient study was two topical applications with an interval of one week. A newer study investigated a formulation at 5% Quassia amara inclusion. In the 2012 Mac-Mary et al. trial, 30 patients applied the treatment one to three times, 5 days apart, with cure defined as absence of live lice after 5, 10, or 14 days.

For rosacea studies: 30 patients were treated with a topical gel with 4% Quassia amara extract for 6 weeks.

For seborrheic dermatitis: 60 patients were given a topical gel with 4% Quassia amara extract for 4 weeks.

For antifertility animal studies: Q. amara extract (100 mg/kg p.o.) and quassin (0.1 and 2 mg/kg p.o.) were administered daily for 6 weeks to male rats.

For the antiulcer animal study: oral extract doses of 800 mg/kg provided 77–85% cytoprotective efficacy against indomethacin-induced gastric ulcers in rat models.

7. Safety Considerations and Interactions

7.1 Regulatory Status

Quassia is listed as generally regarded as safe (GRAS) by the FDA. This designation applies to its use as a flavoring agent in food products.

7.2 Oral Gastrointestinal Irritation

Large amounts given orally have been known to irritate the mucus membrane in the stomach and may lead to vomiting.

7.3 Cardiac and Anticoagulant Interactions

Excessive use may also interfere with existing cardiac and anticoagulant regimens. The specific pharmacokinetic mechanism for these interactions has not been fully elucidated in the literature reviewed.

7.4 Male Reproductive Toxicity

This is a well-documented safety concern supported by multiple independent animal studies. There are preliminary reports implicating this plant in male reproductive toxicology; its bioactive principle quassin has been reported as the antifertility agent. Epididymal sperm counts, serum levels of testosterone, luteinizing hormone (LH), and follicle stimulating hormone (FSH) were significantly reduced when rats were treated with the extract.

The crude methanol extract of the stem wood significantly caused a reduction in the weight of the testis, epididymis, and seminal vesicle. A marked decrease in sperm count, motility, and viability was also observed in sperm collected from the cauda epididymis of treated animals. A number of abnormalities—including double heads, double tails, detached heads, and fragile tails—were frequently seen. The prime site of action appears to be at the level of both the testis and the epididymis.

Different fractions of Quassia amara and its bioactive compound quassin have been implicated in male reproductive toxicology. These antifertility activities have been observed in both in vivo and in vitro animal models. Notably, reversible anti-fertility action of Quassia amara extract has been demonstrated in rats, suggesting the effect may not be permanent, though clinical data in humans are entirely absent.

7.5 Pregnancy

Because of the plant's cytotoxic and emetic properties, its use during pregnancy should be avoided.

7.6 Acute Oral Toxicity Data (Animal)

Acute oral toxicity assessed by the OECD limit test procedure showed that methanol extract of Quassia amara produced no lethality up to 5,000 mg/kg in rats. No formal human toxicity profiles, no-observed-adverse-effect levels (NOAELs), or maximum safe doses have been established for Quassia amara in clinical populations, as all safety data derive from animal experiments.

7.7 Topical Safety

No adverse reactions were reported upon topical application of the scalp preparation in the 454 patients in the head lice study. In the rosacea clinical trial, no side effects such as pruritus, edema, or stinging were observed.

7.8 Cytotoxicity and the Bruceantin Precedent

In the context of antimalarial treatment, it appeared that the dose necessary for obtaining a curative antimalarial effect is close to the toxic dose of an SkD analogue (bruceantin). Prior to emitting a definitive conclusion, a clinical study in humans similar to the one done with bruceantin should be performed. This caution is supported by the fact that due to serious toxicity (hypotension, nausea, vomiting, and fever) and poor efficacy, clinical trials of bruceantin failed.

7.9 Botanical Identity Confusion and Quality Considerations

Bitter-tasting plants are essential natural resources in traditional medicine, but their botanical identity has been a matter of controversy. Despite the long history of using Q. amara, misunderstandings have evolved in the literature due to inconsistent local names and a lack of access to botanical expertise. Because both Quassia amara and Picrasma excelsa are sold under the same name, and because regional confusion with related Simaroubaceae species (such as Picrasma crenata) exists, the precise phytochemical profile of commercial preparations may vary.

References

• Houël E et al. "Quassinoid constituents of Quassia amara L. leaf herbal tea: Impact on antimalarial activity and cytotoxicity." Journal of Ethnopharmacology, 2009. PubMed
• Phytopharmacology Journal: "Quassia amara L." Vol. 11, Issue 3. Phytopharma Journal
• Ogbonnia SO et al. "Antiulcerogenic Effects and Possible Mechanism of Action of Quassia Amara Extract and Its Bioactive Principles in Rats." PMC / PubMed Central
• Wikipedia: "Quassia amara." Wikipedia
• ScienceDirect Topics: "Quassia amara – An Overview." ScienceDirect
• Pavunraj M et al. "Role of quassinoids as potential antimalarial agents: An in silico approach." PMC / PubMed Central, 2016
• Bertani S et al. "New findings on Simalikalactone D, an antimalarial compound from Quassia amara L. (Simaroubaceae)." PubMed, 2012
• Cachet N et al. "Antimalarial activity of simalikalactone E, a new quassinoid from Quassia amara L. (Simaroubaceae)." PubMed, 2009
• Nissen HP, Blitz H, Kreysel HW. "Pediculosis capitis treated with quassia tincture." PubMed, 1978
• Mac-Mary S et al. "Assessment of the Efficacy and Safety of a New Treatment for Head Lice." PMC / International Scholarly Research Notices, 2012
• Research Square: "Evaluating the efficacy of a new lice treatment shampoo containing Quassia Amara using physical and tolerance approaches." 2024
• Ferrari A, Diehl C. "Evaluation of the efficacy and tolerance of a topical gel with 4% quassia extract in the treatment of rosacea." PubMed, 2011
• Diehl C, Ferrari M. "Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis: a randomized, double-blind, comparative study." PubMed, 2013
• Diehl C et al. "Superiority of Quassia Amara 4% Cream over Metronidazole 0.75% Cream in the Treatment of Rosacea: A Randomized, Double-Blinded Trial." Journal of Dermatology and Clinical Research, 2018
• Augustin M et al. "New Herbal Biomedicines for the Topical Treatment of Dermatological Disorders." PMC / Pharmaceuticals, 2020
• Parveen N et al. "A comprehensive evaluation of the reproductive toxicity of Quassia amara in male rats." ScienceDirect / Birth Defects Research, 2003
• Njar VC et al. "Antifertility activity of Quassia amara: quassin inhibits the steroidogenesis in rat Leydig cells in vitro." PubMed, 1995
• The Physiological Society: "In vivo and in vitro reproductive toxicity of Quassia amara extract and Quassin." Abstract
• Drugs.com Natural Products: "Quassia Uses, Benefits & Dosage." Reviewed December 2025
• Bertani S et al. "New findings on Simalikalactone D, an antimalarial compound from Quassia amara L. (Simaroubaceae)." ScienceDirect / Experimental Parasitology, 2012
• ResearchGate: "Quassia amara L.: A Comprehensive Review of its Ethnomedicinal Uses, Phytochemistry, Pharmacology and Toxicity." 2022
• Bourdy G et al. "Geopolitics of bitterness: Deciphering the history and cultural biogeography of Quassia amara L." ScienceDirect / Journal of Ethnopharmacology, 2020
• Quasix.eu: "Quassia: A Review — Quassia amara Family Simaroubaceae." Technical monograph
• Academia.edu: "Cytotoxicity and Acute Oral Toxicity Study on Quassin and Fractions of Quassia amara Extract."